• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Veryan’s helical stent meets safety, efficacy endpoints after 12 months

Veryan’s helical stent meets safety, efficacy endpoints after 12 months

February 9, 2018 By Sarah Faulkner

Veryan BiomimicsVeryan‘s helical BioMimics 3D stent met its primary safety and efficacy endpoints in a study of 271 patients with symptomatic femoropopliteal artery disease, according to TCTMD.

The device, which is shaped to mimic the natural geometry of human vasculature, compared favorably with drug-coated balloons and stents.

The probability of maintaining primary patency after 12 months was 81.9% for the BioMimics 3D device. The helical stent was beaten out by Cook Medical‘s Zilver PTX product, which had the highest probability at 82.7%, and Spectranetics‘ Stellarex device at 82.3%. Medtronic‘s (NYSE:MDT) In.Pact balloon had a 78.4% probability of maintaining primary patency after one year, followed by C.R. Bard‘s (NYSE:BCR) Lutonix device at 73.5%.

At the International Symposium on Endovascular Therapy, Dr. Timothy Sullivan reportedly explained that the curvature of the device promotes a swirling flow of blood, which increases wall shear stress and serves an “alternative to antiproliferative drugs.”

Veryan’s device won CE Mark approval in 2012 and the company is conducting clinical trials in the hopes of winning approval for the stent in the U.S., Germany and Japan.

The study, Mimics-2, found that patients who were treated with the device had a 99.6% rate of freedom from major adverse events through 30 days.

After one year, freedom from clinically-driven target lesion revascularization was 88.4%, according to TCTMD. Veryan plans to follow the patients enrolled in Mimics-2 for 36 months.

Filed Under: Clinical Trials, Drug-Device Combinations, Pharmaceutical, Vascular, Wall Street Beat Tagged With: C.R. Bard, Cook Medical, Medtronic, Spectranetics Corp., Veryan

More recent news

  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech
  • GE HealthCare launches new MRI scanner
  • HistoSonics earns first major reimbursement win for non-invasive histotripsy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy